COMPARATIVE ANALYSIS OF PHARMACOKINETIC (PK) STUDY DATA BETWEEN EXTENDED HALF-LIFE (EHL) AND STANDARD HALF-LIFE (SHL) FACTOR PRODUCTS: EXPERIENCE FROM GREEK ADULT HAEMOPHILIA CENTRE

被引：0
|
作者：
Christoforou, P. [1 ,2 ]
Kourampa, A. [1 ,2 ]
Varaklioti, A. [1 ,2 ]
Pirpiri, T. [1 ,2 ]
Balomenou, A. [1 ,2 ]
Katsarou, O. [1 ,2 ]
机构：
[1] Laikon Gen Hosp, Blood Unit, Athens, Greece
[2] Laikon Gen Hosp, Natl Reference Ctr Congenital Bleeding Disorders, Athens, Greece
来源：
HAEMOPHILIA | 2023年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
PO074
引用
收藏
页码：61 / 61
页数：1
相关论文
共 50 条
  • [41] EXTENDED HALF-LIFE COAGULATION FACTOR IX IN HAEMOPHILIA B PROPHYLAXIS: A COST-EFFECTIVENESS ANALYSIS
    Iannazzo, S.
    Cortesi, P. A.
    Myren, K.
    Eldar-Lissai, A.
    Mantovani, L. G.
    VALUE IN HEALTH, 2016, 19 (07) : A587 - A587
  • [42] The changing treatment landscape in haemophilia: from standard half-life clotting factor concentrates to gene editing
    Mancuso, Maria Elisa
    Mahlangu, Johnny N.
    Pipe, Steven W.
    LANCET, 2021, 397 (10274): : 630 - 640
  • [43] Switching from standard to extended half-life FVIII prophylaxis in haemophilia A: Comparison of factor product use, bleed rates and pharmacokinetics
    Nummi, Vuokko
    Lehtinen, Anna-Elina
    Iorio, Alfonso
    Szanto, Timea
    Lassila, Riitta
    HAEMOPHILIA, 2022, 28 (06) : E237 - E244
  • [44] Transitioning from standard to extended half-life factor VIII concentrates - correlating dosing strategy with subsequent pharmacokinetic study and bleeding events
    Tan, Pamela
    Yeam, Shin
    Cheong, May Anne
    Tan, Chuen Wen
    Lee, Lai Heng
    Tien, Sim Leng
    Ng, Heng Joo
    HAEMOPHILIA, 2024, 30 : 148 - 149
  • [45] REAL-LIFE EXPERIENCE IN SWITCHING TO A NEW EXTENDED HALF-LIFE FIX PRODUCT AT A PORTUGUESE HAEMOPHILIA CENTRE: FIRST IMPRESSIONS AND ESTIMATED RESULTS
    Catarino, C.
    Campanico, S.
    Rodrigues, F.
    Pereira, A.
    HAEMOPHILIA, 2021, 27 : 114 - 114
  • [46] Validation of factor VIII activity for monitoring standard and extended half-life products and correlation to thrombin generation assays
    Augustsson, Cecilia
    Norstrom, Eva
    Lind, Vivian
    Martin, Myriam
    Astermark, Jan
    Strandberg, Karin
    HAEMOPHILIA, 2021, 27 (03) : 494 - 500
  • [47] Danish clinical experience of switching from standard half-life FVIII to damoctocog alfa pegol in patients with haemophilia A
    Poulsen, L. H.
    Adamsen, I.
    HAEMOPHILIA, 2024, 30 : 102 - 102
  • [48] Canadian clinical experience on switching from standard half-life recombinant factor VIII (rFVIII), octocog alfa, to extended half-life rFVIII, damoctocog alfa pegol, in persons with haemophilia A ≥ 12 years followed in a Comprehensive Hemophilia Care Program in Canada
    Matino, Davide
    Germini, Federico
    Chan, Anthony K. C.
    Decker, Kay
    Iserman, Emma
    Chelle, Pierre
    Edginton, Andrea N.
    Oladoyinbo, Olayide
    Trinari, Elisabetta
    Keepanasseril, Arun
    Iorio, Alfonso
    HAEMOPHILIA, 2024, 30 (02) : 345 - 354
  • [49] Real-world analysis of the PK-guided switch from standard half-life factor VIII to efmoroctocog alfa
    Megias-Vericata, J. E.
    Boix, S. Bonanad
    Haro, A. R. Cid
    Guaita, S. Haya
    Aguilar-Rodriguez, M.
    Marques-Minana, M. R.
    Bosch, P.
    Andres, J. L. Poveda
    THROMBOSIS RESEARCH, 2024, 233 : 135 - 137
  • [50] FVIII dosages in persons with haemophilia A treated with extended half-life products: From local biology to optimized patient management
    Perrier-Cornet, Andreas
    Philippe, Aurelien
    Lambert, Thierry
    d'Oiron, Roseline
    Rafowicz, Anne
    Lavenu-Bombled, Cecile
    Combe, Sophie
    Gillibert, Andre
    Proulle, Valerie
    HAEMOPHILIA, 2019, 25 (06) : E361 - E363
12345